Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.
Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial.
复制标题
DOI：
10.1002/cncr.31368
复制
发表时间：
2018-06-15
期刊：
影响因子：
6.2
通讯作者：
Jones LW
中科院分区：
文献类型：
--
作者：
Scott JM;Iyengar NM;Nilsen TS;Michalski M;Thomas SM;Herndon J 2nd;Sasso J;Yu A;Chandarlapaty S;Dang CT;Comen EA;Dickler MN;Peppercorn JM;Jones LW
Investigation of exercise training in metastatic breast cancer has received minimal attention. We determined the feasibility and safety of aerobic training in metastatic breast cancer. 65 women (21 to 80 years) with metastatic (stage IV) breast cancer (57% receiving chemotherapy; >40% ≥ 2 lines of prior therapy) were allocated to an aerobic training (n=33) or stretching (n=32) group. Aerobic training consisted of 36 supervised treadmill walking sessions delivered thrice-weekly between 55% to 80% of peak oxygen consumption (VO2peak) for 12 consecutive weeks. Stretching was matched to aerobic training on location, frequency, duration, and intervention length. The primary end point was aerobic training feasibility a priori defined as rate of lost to follow up (LTF) (<20%) and attendance (≥70%). Secondary end points were safety, objective (VO2peak, functional capacity) and patient-reported (quality of life) outcomes. One of 33 (3%) patients receiving aerobic training was LTF whereas mean attendance was 63% ± 30%. Rates of permanent discontinuation and dose modification were 27% and 49%, respectively. Intention-to-treat analyses indicated improvements in patient-reported outcomes (PROs), favoring the attention control group (p’s>0.05). Per protocol analyses indicated 14 of 33 (42%) patients receiving aerobic training had acceptable tolerability (relative dose intensity ≥70%), which led to improvements in VO2peak and functional capacity (p’s <0.05). Aerobic training at the dose and schedule tested is safe but not feasible in a significant proportion of patients with metastatic breast cancer. The acceptable feasibility and promising benefit in select patients warrants further evaluation in a dose-finding phase 1/2 study.
登录
查看更多内容
DOI：
10.1093/jnci/djp235
发表时间：
2009-09-02
期刊：
Journal of the National Cancer Institute
影响因子：
--
作者：
Cardoso F;Bedard PL;Winer EP;Pagani O;Senkus-Konefka E;Fallowfield LJ;Kyriakides S;Costa A;Cufer T;Albain KS;ESO-MBC Task Force
通讯作者：
ESO-MBC Task Force
影响因子：
45.3
作者：
Jones, Lee W.;Courneya, Kerry S.;Haykowsky, Mark
通讯作者：
Haykowsky, Mark
DOI：
10.1111/j.1532-5415.1991.tb01616.x
发表时间：
1991-02-01
影响因子：
6.3
作者：
PODSIADLO, D;RICHARDSON, S
通讯作者：
RICHARDSON, S
影响因子：
3.7
作者：
Steins Bisschop CN;Courneya KS;Velthuis MJ;Monninkhof EM;Jones LW;Friedenreich C;van der Wall E;Peeters PH;May AM
通讯作者：
May AM
影响因子：
6.2
作者：
Ligibel, Jennifer A.;Giobbie-Hurder, Anita;Winer, Eric P.
通讯作者：
Winer, Eric P.